

10/522259

DT01 Rec'd PCT/PT 25 JAN 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Guo Q. Shi, et al

Int'l Appln.
No. : PCT/US03/23430Int'l Date
Filed : 25 July 2003 (07/25/2003)

Serial No. : (To be assigned) Case No.: 21096P

Filed : January 25, 2005

For : PPAR ALPHA SELECTIVE COMPOUNDS FOR THE
TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID
DISORDERSCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 1-25-2005
EXPRESS MAIL NO. EL 989587831 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Kari Schepisi
DATE 1-25-05

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of references other than the US patents and published patent applications that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 

James L. McGinnis

Reg. No. 34,387

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0641

Date: January 25, 2005

INFORMATION DISCLOSURE

(use as many sheets as necessary)

Sheet

2

of

2

Attorney Docket Number

21096P

COMPLETE IF KNOWN**Application Number**

PCT/US03/23430

Filing Date

January 25, 2005

First Named Inventor

Guo Q. Shi, et al

Group Art Unit

Examiner Name

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Database HCAPLUS on STN Online, No. 1989:553565.

Cohen et al, "3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists," *Journal of Medicinal Chemistry*, 1989, 32(8), 1842-60.

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003